Molecule News and Research

RSS

Amylin behaves when guarded by zinc

In type 2 diabetes, a protein called amylin forms dense clumps that shut down insulin-producing cells, wreaking havoc on the control of blood sugar. But zinc has a knack for preventing amylin from misbehaving.

1 Jul 2011

Scientists discover enzyme that can regulate breast cancer development

Researchers at Cold Spring Harbor Laboratory (CSHL) have identified an enzyme that appears to be a significant regulator of breast cancer development. Called PTPN23, the enzyme is a member of a family called protein tyrosine phosphatases, or PTPs, that plays a fundamental role in switching cell signaling on and off.

1 Jul 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

TCGA examines ovarian serous adenocarcinoma tumors from 500 patients

An analysis of genomic changes in ovarian cancer has provided the most comprehensive and integrated view of cancer genes for any cancer type to date. Ovarian serous adenocarcinoma tumors from 500 patients were examined by The Cancer Genome Atlas (TCGA) Research Network and analyses are reported in the June 30, 2011, issue of Nature.

30 Jun 2011

Modulating interaction between 'rotten eggs' gas and nitric oxide may treat heart failure

Research carried out by scientists from the Peninsula Medical School at the University of Exeter and the National University of Singapore has analysed the complex 'cross talk' between hydrogen sulphide and nitric oxide, both gasses that occur naturally in the body, and found that the interaction may offer potential strategies in the management of heart failure.

30 Jun 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011

Rodent olfaction and the chemistry of instinct

The mechanics of instinctive behavior are mysterious. Even something as simple as the question of how a mouse can use its powerful sense of smell to detect and evade predators, including species it has never met before, has been almost totally unknown at the molecular level until now.

29 Jun 2011

Prototype small molecule drugs could suppress hepatitis C

Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK.

29 Jun 2011

Combination therapies inhibiting P7 could prevent spread of HCV

British researchers have identified specific resistance mutations for two classes of p7 inhibitor, which may explain their lack of effectiveness in clinical trials combined with current standard of care.

29 Jun 2011

Biolauncher, Isogenica and Cresset enter joint venture to develop drug discovery platform

Isogenica Ltd today announced a collaborative joint venture with Biolauncher Ltd and Cresset Biomolecular Discovery Ltd to develop an innovative end-to-end therapeutic discovery platform.

28 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

Researchers identify how sooty mangabeys survive SIV infection

Sooty mangabeys, a type of African monkey, have intrigued scientists for years because they can survive infection by SIV, a relative of HIV, and not succumb to AIDS.

27 Jun 2011

Genentech, FORMA enter structurally innovative agreement for small molecule cancer program

FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group, exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.

27 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

Rogue super-activated neutrophils may cause organ damage in parts unconnected to injury

A study from scientists at Queen Mary, University of London, sheds new light on why people who experience serious trauma or go through major surgery, can suffer organ damage in parts of the body which are seemingly unconnected to the injury.

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Promising results of the Phase I clinical trial of the generic drug BCG to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego.

27 Jun 2011

Researchers develop new way to search for RNA drug targets

By accounting for the floppy, fickle nature of RNA, researchers at the University of Michigan and the University of California, Irvine have developed a new way to search for drugs that target this important molecule. Their work appears in the June 26 issue of Nature Chemical Biology.

27 Jun 2011

Department of Defense awards Impel Phase II SBIR grant for blood-brain barrier bypass technology

Impel NeuroPharma, a medical device company whose technology is designed to enable pharmaceutical drugs to bypass the blood-brain barrier and enter the central nervous system (CNS), today announced that it was selected to receive a Phase II Small Business Investigational Research (SBIR) grant from the Department of Defense's Chemical and Biological Defense SBIR Program entitled, "Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents."

24 Jun 2011

Molecule News and Research

Amylin behaves when guarded by zinc

Scientists discover enzyme that can regulate breast cancer development

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

TCGA examines ovarian serous adenocarcinoma tumors from 500 patients

Modulating interaction between 'rotten eggs' gas and nitric oxide may treat heart failure

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Rodent olfaction and the chemistry of instinct

Prototype small molecule drugs could suppress hepatitis C

Combination therapies inhibiting P7 could prevent spread of HCV

Biolauncher, Isogenica and Cresset enter joint venture to develop drug discovery platform

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

Researchers identify how sooty mangabeys survive SIV infection

Genentech, FORMA enter structurally innovative agreement for small molecule cancer program

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

Rogue super-activated neutrophils may cause organ damage in parts unconnected to injury

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

Promising results from MGH's BCG Phase I trial on type I diabetes

Researchers develop new way to search for RNA drug targets

Department of Defense awards Impel Phase II SBIR grant for blood-brain barrier bypass technology

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News